Tagrisso (osimertinib) has not received FDA approval in 2024 for any new indications. The drug's current FDA approvals are for specific types of non-small cell lung cancer (NSCLC) [1].
What are Tagrisso's current FDA-approved uses?
Tagrisso is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with epidermal growth factor receptor (EGFR) mutation-positive NSCLC. This includes:
* First-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations as detected by an FDA-approved test [2].
* Treatment of patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after a prior EGFR tyrosine kinase inhibitor (TKI) therapy [2].
* Adjuvant treatment following complete tumor resection in adult patients with NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations as detected by an FDA-approved test [2].
When was Tagrisso first approved by the FDA?
Tagrisso received its initial FDA approval on November 13, 2015, for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC who had progressed on or after a prior chemotherapy regimen [2].
What are the latest developments with Tagrisso and the FDA?
While no new FDA approvals for Tagrisso have been announced in 2024, regulatory bodies often review new data and submissions throughout the year. Pharmaceutical companies continuously conduct clinical trials to explore new uses and refine existing treatments. Information regarding potential future approvals or expanded indications would typically be found on the FDA's official website or through company announcements.
How does Tagrisso work?
Tagrisso is a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI). It targets specific mutations in the EGFR gene, which are common drivers of NSCLC growth. By inhibiting these mutated EGFR pathways, Tagrisso can help slow or stop cancer cell proliferation [3].
What is the patent status for Tagrisso?
Information regarding drug patents, including expiry dates and any ongoing litigation, can be found on specialized databases. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals [4]. Patent protection is crucial for drug manufacturers as it grants them exclusive rights to market and sell their products for a specified period.
Who manufactures Tagrisso?
Tagrisso is manufactured by AstraZeneca [2].
What clinical trials is Tagrisso currently involved in?
AstraZeneca is actively conducting clinical trials for Tagrisso. These trials explore its efficacy in various stages of NSCLC, in combination with other therapies, and for different patient populations. Information on ongoing clinical trials can typically be found on clinical trial registries and through the manufacturer's official channels.
Sources:
1. FDA.gov
2. AstraZeneca website
3. National Cancer Institute website
4. DrugPatentWatch.com